Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Factor to reveal mRNA-based iPS cell-derived macrophages for solid-tumor targeting, allogeneic iPS cell-derived cytotoxic lymphocytes, and advanced targeted insertion technologies.
Lead Product(s): mRNA-based iPSC-derived Macrophage
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
The deal would allow Brooklyn to utilize an extensively patented process to seek to develop gene edited compounds using mRNA, which preclinical data suggest to be more efficient, non-immunogenic and non-mutagenic, for treatment of several solid tumor and liquid indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Brooklyn ImmunoTherapeutics
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2021